MedPath

BEIGENE USA, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

16

Active:14
Completed:2

Trial Phases

2 Phases

Phase 1:15
Phase 2:1

Drug Approvals

2

FDA:2

Drug Approvals

TEVIMBRA

Approval Date
Mar 16, 2024
FDA

BRUKINSA

Approval Date
Mar 8, 2024
FDA

Clinical Trials

Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials

Phase 1
15 (93.8%)
Phase 2
1 (6.3%)

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
Interventions
Radiation: Radiation
First Posted Date
2017-05-12
Last Posted Date
2025-02-04
Lead Sponsor
BeiGene USA, Inc.
Target Recruit Count
116
Registration Number
NCT03150862
Locations
🇺🇸

Center For Neurosciences, Tucson, Arizona, United States

🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

University of California At San Francisco, San Francisco, California, United States

and more 19 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.